Focetria

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
13-02-2015
Summary of Product characteristics Summary of Product characteristics (SPC)
13-02-2015
Public Assessment Report Public Assessment Report (PAR)
05-10-2010

Active ingredient:

Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/California/7/2009 (H1N1)-derived strain used NYMC X-181

Available from:

Novartis Vaccines and Diagnostics S.r.l.

ATC code:

J07BB02

INN (International Name):

influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)

Therapeutic group:

Грипни ваксини

Therapeutic area:

Influenza, Human; Immunization; Disease Outbreaks

Therapeutic indications:

Профилактика на грип, причинена от вирус A (H1N1v) 2009. Focetria трябва да се използва в съответствие с официалните насоки.

Product summary:

Revision: 9

Authorization status:

Отменено

Authorization date:

2007-05-02

Patient Information leaflet

                                36
Б. ЛИСТОВКА
Лекарствен продукт с невалидно
разрешение за употреба
37
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
FOCETRIA ИНЖЕКЦИОННА СУСПЕНЗИЯ
Influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)
Ваксина срещу грип H1N1v (повърхностни
антигени, инактивирани, с адювант)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ВИ БЪДЕ ПРИЛОЖЕНА ТАЗИ
ВАКСИНА, ТЪЙ
КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни въ
проси, попитайте Вашия лекар или
медицинска
сестра.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар. Това
включва и всички възможни нежелани
реакции, неописани в тази листовка.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
:
1.
Какво представлява Focetria и за какво се
използва
2.
Какво трябва да знаете, преди да Ви
бъде приложена Focetr
i
a
3.
Как ще Ви бъде приложена Focetria
4.
Възможни нежелани реакции
5.
Как да съхранявате Focetria
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА FOCETRIA И ЗА КАКВО СЕ
ИЗПОЛЗВА
Focetria е ваксина за предпазване срещу
грип, причинен от A(H1N1v) 2009 вирус.
Когато човек се ваксинира, имунната
система (естественат
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАР
А
КТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Focetria инжекционна суспензия в
предварително напълнена спринцовка
Ваксина срещу грип H1N1v (повърхностни
антигени, инактивирани, с адювант)
_(Influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted))
_
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Повърхностни антигени на грипен вирус
(хемаглутинин и невраминидаза)* от щам:
A/California/07/2009 (H1N1)-производeн щам NYMC X-181
7,5 микрограма** за доза от 0,5 ml
* произведени в яйца
** изразен в микрограма хемаглутинин.
Адюван
т M
F59C.1, съдържащ:
сквален
9,75 милиграма
полисорбат 80
1,175 милиграма
сорбитанов триолеат
1,175 милиграма
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Инжекционна суспензия в
предварително напълнена спринцовка.
Млечно-бяла течност.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Профилактика на грип, причинен от A(H1N1v)
2009 вирус (вж. точкa 4.4).
Focetria трябва да се използва в
съответствие с офици
ални
те указания.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Препоръките за дозиране вземат
предвид данните за безопасност и
имуногенност от клинични
проучвания пр
                                
                                Read the complete document

Similar products

Active ingredient Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/California/7/2009 (H1N1)-derived strain used NYMC X-181

Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/California/7/2009 (H1N1)-derived strain used NYMC X-181

ATC code J07BB02

J07BB02

Marketed by Novartis Vaccines and Diagnostics S.r.l.

Novartis Vaccines and Diagnostics S.r.l.

INN (International Name) influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)

influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 13-02-2015
Summary of Product characteristics Summary of Product characteristics Spanish 13-02-2015
Public Assessment Report Public Assessment Report Spanish 05-10-2010
Patient Information leaflet Patient Information leaflet Czech 13-02-2015
Summary of Product characteristics Summary of Product characteristics Czech 13-02-2015
Public Assessment Report Public Assessment Report Czech 05-10-2010
Patient Information leaflet Patient Information leaflet Danish 13-02-2015
Summary of Product characteristics Summary of Product characteristics Danish 13-02-2015
Public Assessment Report Public Assessment Report Danish 05-10-2010
Patient Information leaflet Patient Information leaflet German 13-02-2015
Summary of Product characteristics Summary of Product characteristics German 13-02-2015
Public Assessment Report Public Assessment Report German 05-10-2010
Patient Information leaflet Patient Information leaflet Estonian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Estonian 13-02-2015
Public Assessment Report Public Assessment Report Estonian 05-10-2010
Patient Information leaflet Patient Information leaflet Greek 13-02-2015
Summary of Product characteristics Summary of Product characteristics Greek 13-02-2015
Public Assessment Report Public Assessment Report Greek 05-10-2010
Patient Information leaflet Patient Information leaflet English 13-02-2015
Summary of Product characteristics Summary of Product characteristics English 13-02-2015
Public Assessment Report Public Assessment Report English 05-10-2010
Patient Information leaflet Patient Information leaflet French 13-02-2015
Summary of Product characteristics Summary of Product characteristics French 13-02-2015
Public Assessment Report Public Assessment Report French 05-10-2010
Patient Information leaflet Patient Information leaflet Italian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Italian 13-02-2015
Public Assessment Report Public Assessment Report Italian 05-10-2010
Patient Information leaflet Patient Information leaflet Latvian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Latvian 13-02-2015
Public Assessment Report Public Assessment Report Latvian 05-10-2010
Patient Information leaflet Patient Information leaflet Lithuanian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-02-2015
Public Assessment Report Public Assessment Report Lithuanian 05-10-2010
Patient Information leaflet Patient Information leaflet Hungarian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Hungarian 13-02-2015
Public Assessment Report Public Assessment Report Hungarian 05-10-2010
Patient Information leaflet Patient Information leaflet Maltese 13-02-2015
Summary of Product characteristics Summary of Product characteristics Maltese 13-02-2015
Public Assessment Report Public Assessment Report Maltese 05-10-2010
Patient Information leaflet Patient Information leaflet Dutch 13-02-2015
Summary of Product characteristics Summary of Product characteristics Dutch 13-02-2015
Public Assessment Report Public Assessment Report Dutch 05-10-2010
Patient Information leaflet Patient Information leaflet Polish 13-02-2015
Summary of Product characteristics Summary of Product characteristics Polish 13-02-2015
Public Assessment Report Public Assessment Report Polish 05-10-2010
Patient Information leaflet Patient Information leaflet Portuguese 13-02-2015
Summary of Product characteristics Summary of Product characteristics Portuguese 13-02-2015
Public Assessment Report Public Assessment Report Portuguese 05-10-2010
Patient Information leaflet Patient Information leaflet Romanian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Romanian 13-02-2015
Public Assessment Report Public Assessment Report Romanian 05-10-2010
Patient Information leaflet Patient Information leaflet Slovak 13-02-2015
Summary of Product characteristics Summary of Product characteristics Slovak 13-02-2015
Public Assessment Report Public Assessment Report Slovak 05-10-2010
Patient Information leaflet Patient Information leaflet Slovenian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Slovenian 13-02-2015
Public Assessment Report Public Assessment Report Slovenian 05-10-2010
Patient Information leaflet Patient Information leaflet Finnish 13-02-2015
Summary of Product characteristics Summary of Product characteristics Finnish 13-02-2015
Public Assessment Report Public Assessment Report Finnish 05-10-2010
Patient Information leaflet Patient Information leaflet Swedish 13-02-2015
Summary of Product characteristics Summary of Product characteristics Swedish 13-02-2015
Public Assessment Report Public Assessment Report Swedish 05-10-2010
Patient Information leaflet Patient Information leaflet Norwegian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Norwegian 13-02-2015
Patient Information leaflet Patient Information leaflet Icelandic 13-02-2015
Summary of Product characteristics Summary of Product characteristics Icelandic 13-02-2015
Patient Information leaflet Patient Information leaflet Croatian 13-02-2015
Summary of Product characteristics Summary of Product characteristics Croatian 13-02-2015

Search alerts related to this product

Alerts Focetria Influenza virus surface antigens vaccine H1N1v

Focetria Influenza virus surface antigens vaccine H1N1v

View documents history

Documents history Documents history

Focetria